...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Current pharmaceutical design >Personalized Therapies in Pediatric Inflammatory and Autoimmune Diseases
【24h】

Personalized Therapies in Pediatric Inflammatory and Autoimmune Diseases

机译：小儿炎症和自身免疫性疾病的个性化疗法

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Pediatric inflammatory and autoimmune diseases are a wide array of systemic or organ-specific conditions, characterized by an exaggerated immune reactivity, which generally occurs in immunogenetically predisposed children. Among the most important ones, in terms of their diffusion and morbidity in the population worldwide, pediatric inflammatory bowel disease (IBD) and juvenile rheumatoid arthritis (JRA) have to be considered. The aim of personalized therapy is to give to each patient the most appropriate drug and dose regimen, in order to maximize treatment response and reduce the risk of adverse events. In general, several therapeutic options exist for pediatric inflammatory and autoimmune conditions, therefore the perspective of pharmacological tools that allow identification of patients with increased risk of treatment issues related to a particular medication, in terms of lack of efficacy or increased probability of adverse events, is particularly desirable and promising. The present review will be focused on the personalized therapy approaches already available or in development for pediatric patients with IBD or JRA, comprising pharmacokinetic, pharmacodynamic and pharmacogenetic assays.
机译：小儿炎症性和自身免疫性疾病是广泛的全身或器官特异性疾病，其特征是免疫反应性过高，通常发生在有免疫遗传倾向的儿童中。在最重要的疾病中，就其在全世界人群中的扩散和发病率而言，必须考虑小儿炎症性肠病（IBD）和青少年类风湿性关节炎（JRA）。个性化治疗的目的是为每个患者提供最合适的药物和剂量方案，以最大程度地提高治疗效果并降低不良事件的风险。通常，对于小儿炎症和自身免疫性疾病，存在几种治疗选择，因此，从药理学工具的角度考虑，可以从缺乏功效或不良事件发生几率方面确定与特定药物相关的治疗问题风险增加的患者，是特别理想和有希望的。本综述将集中于针对已有IBD或JRA患儿的患者已经可用或正在开发的个性化治疗方法，包括药代动力学，药代动力学和药代遗传学测定。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号